The impact of drug resistance on the global tuberculosis epidemic

International Journal of Tuberculosis and Lung Disease

Volumn 4, Issue 2 SUPPL. 1, 2000, Pages

  Schluger, N W ^a  

^a Columbia Univ Coll Phys Surgs ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; CONFERENCE PAPER; DRUG CONTROL; EPIDEMIC; FINANCIAL MANAGEMENT; HEALTH CARE AVAILABILITY; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIGRATION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HUMANS; RISK FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH;

EID: 0034048344     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (32)

1. Harris H. Chemotherapy of tuberculosis: the beginning. In: Rom W, Garay S, eds. Tuberculosis. Boston: Little, Brown, 1996: 745-750.
2. Schluger N, Harkin T, Rom W. Principles of therapy of tuberculosis. In: Rom WN, Garay S, eds. Tuberculosis. Boston: Little Brown, 1996.
3. Ridzon R, Whitney C G, McKenna M T, et al. Risk factors for rifampin mono resistant tuberculosis. Am J Respir Crit Care Med 1998; 157: 1881-1884.
4. Munsiff S S, Joseph S, Ebrahimzadeh A, Frieden T R. Rifampin-monoresistant tuberculosis in New York City, 1993-1994. Clin Infect Dis 1997; 25: 1465-1467.
5. Sandman L, Schluger N W, Davidow A L, Bonk S. Risk factors for rifampin-monoresistant tuberculosis: a case-control study. Am J Respir Crit Care Med 1999; 159: 468-472.
6. Hopewell P C, Sanchez Hernandez M, Baron R B, Ganter B. Operational evaluation of treatment for tuberculosis. Results of a 'standard' 12-month regimen in Peru. Am Rev Respir Dis 1984; 129: 439-443.
7. Manalo F, Tan F, Sbarbaro J A, Iseman M D. Community-based short-course treatment of pulmonary tuberculosis in a developing nation. Initial report of an eight-month, largely intermittent regimen in a population with a high prevalence of drug resistance [see comments]. Am Rev Respir Dis 1990; 142: 1301-1305.
8. Frieden T R, Sterling T, Pablos-Mendez A, Kilburn J O, Cauthen G M, Dooley S W. The emergence of drug resistant tuberculosis in New York City. N Engl J Med 1993; 328: 521-526.
9. Edlin B R, Tokars J I, Grieco M H, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome [see comments]. N Engl J Med 1992; 326: 1514-1521.
10. Fischl M A, Uttamchandani R B, Daikos G L, et al. An out-break of tuberculosis caused by multiple-drug resistant tubercle bacilli among patients with HIV infection [see comments]. Ann Intern Med 1992; 117: 177-183.
11. Bifani P J, Plikayris B B, Kapur V, et al. Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family. JAMA 1996; 275: 452-457.
12. Goble M, Iseman M D, Madsen L A, Waite D, Ackerson L, Horsburgh C R, Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527-532.
13. Park M M, Davis A L, Schluger N W, Cohen H, Rom W N. Outcome of MDR TB patients, 1983-1993. Prolonged sur vival with appropriate therapy. Am J Respir Crit Care Med 1996; 153: 317-324.
14. Turett G S, Telzak E E, Torian L V, et al. Improved outcomes for patients with multidrug-resistant tuberculosis. Clin Infect Dis 1995; 21: 1238-1244.
15. Mahmoudi A, Iseman M D. Pitfalls in the care of patients with tuberculosis. Common errors and their association with the acquisition of drug resistance [see comments]. JAMA 1993; 270: 65-68.
16. Frieden T R, Fujiwara P I, Washko R M, Hamburg M A. Tuberculosis in New York City-turning the tide. N Engl J Med 1995; 333: 229-233.
17. Pablos-Mendez A, Raviglione M C, Laszlo A, et al. Global sur veillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tu berculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 1998; 338: 1641-1649.
18. Ritacco V, Di Lonardo M, Reniero A, et al. Nosocomial spread of human immunodeficiency virus related multidrug resistant tuberculosis in Buenos Aires. J Infect Dis 1997; 176: 637-642.
19. Coninx R, Pfyffer G E, Mathieu C, et al. Drug-resistant tuberculosis in prisons in Azerbaijan: case study. BMJ 1998; 316: 1423-1425.
20. Chaulk C P, Moore Rice K, Rizzo R, Chaisson R E. Eleven years of community-based directly observed therapy for tuberculosis. JAMA 1995; 274: 945-951.
21. Blower S M, Small P M, Hopewell P C. Control strategies for tuberculosis epidemics: new models for old problems. Science 1996; 273: 497-500.
22. Coninx R, Mathieu C, Debacker M, et al. First-line tuberculo-sis therapy and drug resistant Mycobacterium tuberculosis in prisons. Lancet 1999; 353: 969-973.
23. Cole S T, Telenti A. Drug resistance in Mycobacterium tuberculosis. Eur Respir J 1995; 20: 701s-713s.
24. Cole S T. Mechanisms of drug resistance in Mycobacterium tuberculosis. Immunobiol 1994; 191: 584-585.
25. Chopra I, Brennan P. Molecular action of anti-mycobacterial agents. Tubercle Lung Dis 1997; 78: 89-98.
26. Cole S T, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-544.
27. Daley C L, Mugusi F, Chen L L, et al. Pulmonary complications of HIV infection in Dar es Salaam, Tanzania. Role of bronchoscopy and bronchoalveolar lavage. Am J Respir Crit Care Med 1996; 154: 105-110.
28. Grzybowski S, Ashley M J, Pinkus G. Chemoprophylaxis in inactive tuberculosis: long-term evaluation of a Canadian trial. Can Med Assoc J 1976; 114: 607-611.
29. Peloquin C A, Nitta A T, Burman W J, et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 1996; 30: 919-925.
30. Zwarenstein M, Schoeman J H, Vundule C, Lombard C J, Tat ley M. Randomised controlled trial of self-supervised and di rectly observed treatment of tuberculosis. Lancet 1998; 352: 1340-1343.
31. Schluger N, Ciotoli C, Cohen D, Johnson H, Rom W N. Comprehensive tuberculosis control for patients at high risk for noncompliance. Am J Respir Crit Care Med 1995; 151: 1486-1490.
32. Farmer P, Kim JY. Community based approaches to the control of multidrug resistant tuberculosis: introducing 'DOTS-plus'. BMJ 1998; 317: 671-674.